Atea Pharmaceuticals, Inc. (AVIR) Form 10-Q — May 12, 2026
Atea Pharmaceuticals, Inc. reported a net loss of $45.4 million for the three months ended March 31, 2026, compared to a net loss of $34.3 million for the same period in 2025. This increase in net loss reflects the company's ongoing significant research and development expenses, particularly for its HCV and HEV product candidates. The company's cash and cash equivalents, along with marketable securities, stood at $256.0 million as of March 31, 2026.
Key figures
- Eps
- 0
- Eps Beat
- 0
- Revenue
- 0
- Total Debt
- 0
- Debt Amount
- 0
- Revenue Yoy
- 0
- Total Assets
- 267076
- Cash Position
- 256006
- Deal Value Usd
- 0
- Interest Rate
- 0
- Gross Proceeds
- 0
- Offering Price
- 0
- Shares Offered
- 0
- Shares Outstanding
- 80027099
Price after filing
1 day: -16.9%7 days: -24.5%30 days: -20.2%
Close on the filing date to close N calendar days later (from $5.50). Historical, not a forecast.
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.